Using a high-throughput drug screen, we identified synergy between inhibition of EZH2 and ATM with specific cytotoxicity in BRCA1-deficient tumor cells, thereby providing a molecularly rationalized approach that could guide clinical investigations of a combined therapy with EZH2 and ATM inhibitors in BRCA1-deficient breast cancer. Here, ATM is linked to breast carcinoma.